AIM: Recent laboratory and epidemiological studies suggest that vitamin D is a potential agent for colorectal cancer prevention. Its function is partially mediated by the vitamin D receptor (VDR). The aim of this study was to investigate whether a novel G (allele "U") >A (allele "u") polymorphism (Tru9I) in the VDR intron 8 region is associated with risk for colorectal adenoma in a colonoscopy-based case-control study. METHODS: Genotyping for a total of 391 subjects was carried out through PCR and restriction fragment length polymorphism. RESULTS: The frequencies of "U" and "u" alleles were 89.3% and 10.7%, respectively. The "Uu" and "uu" genotypes were associated with decreased risk for adenoma (OR, 0.71; 95%CI, 0.40-1.25). The inverse association was more pronounced for multiple adenomas and adenomas that were larger had moderate or greater dysplasia, or were sessile: the odds ratios (ORs) were, 0.51 (95%CI, 0.21-1.24), 0.37 (95%CI, 0.11-1.28), 0.68 (95%CI, 0.33-1.41), and 0.36 (95%CI, 0.13-0.97) respectively. In joint/combined analyses, inverse associations were more obvious among those who had at least one "u" allele and also were younger (OR, 0.60; 95%CI, 0.26-1.37), women (OR, 0.38; 95%CI, 0.17-0.88), did not smoke (OR, 0.39; 95%CI, 0.13-1.23), or took NSAID (OR, 0.38; 95%CI, 0.12-1.25), but no evidence existed for interactions with calcium or vitamin D intake. CONCLUSION: Our findings suggest that the VDR Tru9I polymorphism may be associated with lower risk for colorectal adenoma, particularly in interaction with various risk factors, but not with calcium or vitamin D.
AIM: Recent laboratory and epidemiological studies suggest that vitamin D is a potential agent for colorectal cancer prevention. Its function is partially mediated by the vitamin D receptor (VDR). The aim of this study was to investigate whether a novel G (allele "U") >A (allele "u") polymorphism (Tru9I) in the VDR intron 8 region is associated with risk for colorectal adenoma in a colonoscopy-based case-control study. METHODS: Genotyping for a total of 391 subjects was carried out through PCR and restriction fragment length polymorphism. RESULTS: The frequencies of "U" and "u" alleles were 89.3% and 10.7%, respectively. The "Uu" and "uu" genotypes were associated with decreased risk for adenoma (OR, 0.71; 95%CI, 0.40-1.25). The inverse association was more pronounced for multiple adenomas and adenomas that were larger had moderate or greater dysplasia, or were sessile: the odds ratios (ORs) were, 0.51 (95%CI, 0.21-1.24), 0.37 (95%CI, 0.11-1.28), 0.68 (95%CI, 0.33-1.41), and 0.36 (95%CI, 0.13-0.97) respectively. In joint/combined analyses, inverse associations were more obvious among those who had at least one "u" allele and also were younger (OR, 0.60; 95%CI, 0.26-1.37), women (OR, 0.38; 95%CI, 0.17-0.88), did not smoke (OR, 0.39; 95%CI, 0.13-1.23), or took NSAID (OR, 0.38; 95%CI, 0.12-1.25), but no evidence existed for interactions with calcium or vitamin D intake. CONCLUSION: Our findings suggest that the VDR Tru9I polymorphism may be associated with lower risk for colorectal adenoma, particularly in interaction with various risk factors, but not with calcium or vitamin D.
Authors: Bálazs Györffy; Barna Vásárhelyi; Dóra Krikovszky; László Madácsy; Attila Tordai; Tivadar Tulassay; András Szabó Journal: Eur J Endocrinol Date: 2002-12 Impact factor: 6.664
Authors: Mohammed T Tayeb; Caroline Clark; Neva E Haites; Linda Sharp; Graeme I Murray; Howard L McLeod Journal: Saudi Med J Date: 2004-04 Impact factor: 1.484
Authors: Sonia M Boyapati; Roberd M Bostick; Katherine A McGlynn; Michael F Fina; Walter M Roufail; Kim R Geisinger; Michael Wargovich; Ann Coker; James R Hebert Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-07 Impact factor: 4.254
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Ulrike Peters; Richard B Hayes; Nilanjan Chatterjee; Wen Shao; Robert E Schoen; Paul Pinsky; Bruce W Hollis; Katherine A McGlynn Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-04 Impact factor: 4.254
Authors: H G Pálmer; J M González-Sancho; J Espada; M T Berciano; I Puig; J Baulida; M Quintanilla; A Cano; A G de Herreros; M Lafarga; A Muñoz Journal: J Cell Biol Date: 2001-07-23 Impact factor: 10.539
Authors: Veronika Fedirko; Roberd M Bostick; Michael Goodman; W Dana Flanders; Myron D Gross Journal: Am J Epidemiol Date: 2010-07-22 Impact factor: 4.897
Authors: So Yeon J Kong; Roberd M Bostick; W Dana Flanders; William M McClellan; Bharat Thyagarajan; Myron D Gross; Suzanne Judd; Michael Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-01-17 Impact factor: 4.254
Authors: So Yeon Kong; Michael Goodman; Suzanne Judd; Roberd M Bostick; W Dana Flanders; William McClellan Journal: Ann Epidemiol Date: 2015-01-16 Impact factor: 3.797
Authors: Jinming Zhao; Richart Harper; Aaron Barchowsky; Y P Peter Di Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-05-11 Impact factor: 5.464
Authors: Sonia S Kupfer; Jeffrey R Anderson; Anton E Ludvik; Stanley Hooker; Andrew Skol; Rick A Kittles; Temitope O Keku; Robert S Sandler; Clara Ruiz-Ponte; Sergi Castellvi-Bel; Antoni Castells; Angel Carracedo; Nathan A Ellis Journal: PLoS One Date: 2011-10-27 Impact factor: 3.240
Authors: Mohammed I Khan; Zofia F Bielecka; Mohammad Z Najm; Ewa Bartnik; Jerzy S Czarnecki; Anna M Czarnecka; Cezary Szczylik Journal: Int J Oncol Date: 2013-12-02 Impact factor: 5.650